Bemnifosbuvir

Table of contents

• What is bemnifosbuvir?
• How does bemnifosbuvir work?
• Which conditions is it studied for?
• How is bemnifosbuvir given?
• What do the clinical trials show?
• What side effects are known?

What is bemnifosbuvir?

Bemnifosbuvir is an investigational antiviral substance. It is being developed as a fixed-dose combination with ruzasvir, another antiviral, under the product name bemnifosbuvir/Ruzasvir Fixed Dose Combination (FDC).^[1] The substance is classified in the therapeutic area of virus diseases, specifically hepatitis C virus infection.^[1] Bemnifosbuvir has no marketing authorisation in the product records, meaning it is still an investigational medicine.^[1] The company responsible for the product is Atea Pharmaceuticals, Inc., based in the United States.^[1]

How does bemnifosbuvir work?

Bemnifosbuvir is an antiviral agent being studied for hepatitis C. A published study evaluated potential interactions of bemnifosbuvir with drug transporters, which are proteins that move medicines in and out of cells.^[3] The trial record does not describe the exact molecular target of bemnifosbuvir in detail. The registered Phase 3 trial evaluates whether the combination of bemnifosbuvir and ruzasvir can clear hepatitis C virus from the blood, measured as HCV RNA below the lower limit of quantitation at study week 24.^[1]

Which conditions is it studied for?

• Chronic hepatitis C virus (HCV) infection — a long-term liver infection caused by the hepatitis C virus. The Phase 3 trial studies bemnifosbuvir/ruzasvir in people with this condition.^[1]

How is bemnifosbuvir given?

Bemnifosbuvir is given by mouth as a film-coated tablet.^[1] In the registered trial, it is administered as a fixed-dose combination with ruzasvir, taken orally once daily.^[1] The trial compares 8 or 12 weeks of bemnifosbuvir/ruzasvir against 12 weeks of sofosbuvir/velpatasvir.^[1]

What do the clinical trials show?

One clinical trial is registered for bemnifosbuvir in the EU Clinical Trials Information System. It is a Phase 3, interventional study with a planned enrolment of 880 participants.^[1] The trial is authorised in the EU registry and is described by a third-party source as active but no longer recruiting.^[2] The study evaluates the efficacy of bemnifosbuvir/ruzasvir administered for 8 or 12 weeks once daily versus sofosbuvir/velpatasvir administered for 12 weeks once daily.^[1] The primary outcome is the proportion of subjects achieving HCV RNA less than the lower limit of quantitation at study week 24, which means the virus is no longer detectable in the blood at a meaningful level.^[1] The trial is open-label, meaning participants and researchers know which treatment is being given.^[2]

What side effects are known?

The registered trial record does not list side effects for bemnifosbuvir. The published transporter study does not report side effects either.^[3] No source in the provided data gives a side-effect profile for bemnifosbuvir, so none can be reported here.